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Phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme in 
gluconeogenesis/glyceroneogenesis, which catalyzes the decarboxylation of oxaloacetate to 
phosphoenolpyruvate. In eukaryotes, there are two isozymes present either in the cytosol (PEPCK-
C, PCK1) or the mitochondria (PEPCK-M, PCK2). While PCK1 is found in gluconeogenic tissues 
and has a very clear metabolic function, PCK2 is expressed in non-gluconeogenic cell types, where 
its role remains largely unknown. For example, PCK2 is highly expressed in most cancer cells, 
where it provides a growth advantage to cancer cells in nutrient-poor environments. 
A group of C-8 modified 3-alkyl-1,8-dibenzylxanthine derivatives was described as a novel 
PEPCK-C inhibitor family. We hypothesized that this family of inhibitors could cross-inhibit both 
PEPCK-C and PEPCK-M due to their nearly identical active center. To determine the validity of our 
claim, we studied PEPCK-M target engagement using INH2—the most potent compound of the 
family—and showed similar quantitate inhibitory kinetics to PEPCK-C. Therefore, we validated 
PEPCK-M as a cancer target using INH2 and compared its efficacy to 3-mercaptopicolinic acid, a 
classical, low potency PEPCK-C inhibitor. 
Treatment of colon and breast carcinoma cell lines with INH2 was shown to inhibit cell 
proliferation, and it decreased cell survival in poor-nutrient environments. Inhibition of PEPCK-M 
with INH2 also reduced colony formation in a soft agar model of anchorage-independent growth. 
Finally, we tested the inhibitor in two subcutaneous xenograft models—SW-480 colon carcinoma 
and MDA-MB-231 breast carcinoma. Daily dosing with 8.3 mg/kg of INH2 successfully inhibited 
tumor growth with respect to the vehicle treatment group. There was no weight loss or any sign of 
apparent toxicity induced by the treatment. 
Our results suggest that PEPCK-M is a valid target for cancer treatment with specific inhibitors. 
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